Needham analyst Michael Matson maintained a Buy rating on Steris (STE – Research Report) today and set a price target of $237.00. The company’s shares closed last Wednesday at $203.81.
According to TipRanks.com, Matson is a 4-star analyst with an average return of 3.8% and a 48.2% success rate. Matson covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Cardiovascular Systems, and Zimmer Biomet Holdings.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Steris with a $248.00 average price target, implying a 14.0% upside from current levels. In a report released today, Piper Sandler also maintained a Buy rating on the stock with a $235.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Steris’ market cap is currently $22.46B and has a P/E ratio of 93.74.
Based on the recent corporate insider activity of 55 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of STE in relation to earlier this year. Most recently, in June 2022, Richard Breeden, a Director at STE bought 3,218 shares for a total of $104,134.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
STERIS Plc (Ireland) engages in the manufacture of medical and surgical equipment. The company was founded on December 22, 2016 and is headquartered in Dublin, Ireland.
Read More on STE:
